NTEC Key Statistics, Chart & Performance
The current stock price of NTEC is 9.63 null. In the past month the price decreased by -27.7%. In the past year, price decreased by -71.32%.
NTEC Latest News, Press Relases and Analysis
NTEC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About NTEC
Company Profile
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Company Info
Intec Parent Inc
12 Hartom Street, Har Hotzvim
JERUSALEM 777512 IL
CEO: Jeffrey A. Meckler
Employees: 70
Phone: 97225864657.0
Intec Parent Inc / NTEC FAQ
What does NTEC do?
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
What is the current price of NTEC stock?
The current stock price of NTEC is 9.63 null. The price decreased by -12.48% in the last trading session.
Does NTEC stock pay dividends?
NTEC does not pay a dividend.
What is the ChartMill technical and fundamental rating of NTEC stock?
NTEC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is Intec Parent Inc (NTEC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NTEC.
What is the ownership structure of Intec Parent Inc (NTEC)?
You can find the ownership structure of Intec Parent Inc (NTEC) on the Ownership tab.
NTEC Technical Analysis
NTEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NTEC. Both the profitability and financial health of NTEC have multiple concerns.
NTEC Financial Highlights
Over the last trailing twelve months NTEC reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 80.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
NTEC Forecast & Estimates
3 analysts have analysed NTEC and the average price target is 53.04 null. This implies a price increase of 450.78% is expected in the next year compared to the current price of 9.63.